10th May 2016 07:00
For Immediate Release | 10 May 2016 |
Cello Group plc
('Cello' or the 'Group')
AGM STATEMENT
Cello Group plc (AIM:CLL), the pharmaceutical and consumer strategic marketing group, announces that at the Annual General Meeting this afternoon, Chairman Allan Rich will say:
"The Group has had a good start to the year in both Cello Health and Cello Signal, in line with expectations.
Cello Health (www.cellohealth.com) has experienced a good start to the year, particularly in the Insight and Communications capabilities in both the UK and the US. Several significant new mandates have been secured in these businesses and, combined with successful collaboration between all of the capabilities in Cello Health, the overall income pipeline is robust. Performance in one component of Cello Health Consumer remains slow.
Cello Signal (www.cellosignal.com) has also had a good start to the year, with new and extended client relationships making a positive impact, particularly in Scotland and Cheltenham. Pulsar continues to show strong growth and is now trading profitably.
Progress has been made on the VAT dispute with HMRC as the Group continues to work towards reaching a final settlement.
The Board continues to be confident of a successful full year for 2016."
Enquiries
Cello Group plc (www.cellogroup.com) | |
Mark Scott, Chief Executive | 020 7812 8460 |
Mark Bentley, Group Finance Director | |
Cenkos Securities | |
Bobbie Hilliam | 020 7397 8900 |
Buchanan | |
Mark Edwards, Sophie McNulty, Maddie Seacombe | 020 7466 5000 |
www.buchanan.uk.com
Related Shares:
CLL.L